Cardiosonic Raises $6.1M In Financing Round

Cardiosonic, Inc., a private company developing innovative and proprietary technology in the field of Renal Denervation for the treatment of Hypertension, announced that it has closed on the first $6.1 million of a planned $16.1 million series B financing round. Cardiosonic has successfully developed a high intensity, non-focused therapeutic ultrasound catheter and control system for remote tissue ablation for the treatment of hypertension by Renal Denervation.